Li Ding
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (35)
With the rapid growth of large-scale single-cell omic datasets, omic foundation models (FMs) have emerged as powerful tools for advancing research in life sciences and precision medicine. However, most existing omic FMs rely primarily on numerical transcriptomic data by sorting genes as sequences, while lacking explicit integration of biomedical prior knowledge and signaling interactions that are critical for scientific discovery. Here, we introduce the Text-Omic Signaling Graph (TOSG), a novel data structure that unifies human-interpretable biomedical textual knowledge, quantitative omic data, and signaling network information. Using this framework, we construct OmniCellTOSG, a large-scale resource comprising approximately half million meta-cell TOSGs derived from around 80 million single-cell and single-nucleus RNA-seq profiles across organs and diseases. We further develop CellTOSG-FM, a multimodal graph language FM, to jointly analyze textual, omic and signaling network context. Across diverse downstream tasks, CellTOSG-FM outperforms existing omic FMs, and provides interpretable insights into disease-associated targets and signaling pathways.
Year:
2026
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2025
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2025
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank
Year:
2025
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy. Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
Year:
2025
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2024
Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which are previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA-sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA-sequencing reiterated top candidates, further affirming the ability of single cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (54)
Lawrence Rubinstein
Statistician
National Cancer Institute
Matthew H Bailey
Assistant Professor
Brigham Young University
Jose G. Trevino
Virginia Commonwealth University
Feng Chen
Professor
Washington University in St. Louis
Michael A. Davies
-
Cornelius von Morze
-
Gerburg Wulf
Harvard University
Sherri Davies
Senior Scientist
Washington University in St. Louis
Min Jin Ha
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Song Cao
Assistant Professor
Washington University in St. Louis
William Buchser
Associate Professor
Washington University in St. Louis
Peter Robinson
Professor for Medical Computer Science
The Jackson Laboratory for Genomic Medicine
Jeffrey Chuang
Jackson Laboratory
Cynthia X. Ma
Washington University in Saint Louis School of Medicine
David G. DeNardo
Professor of Medicine
Washington University School of Medicine
Xiaowei Xu
Professor
University of Pennsylvania
Mark Fiala
Assistant Professor
Washington University School of Medicine
Shidan Wang
-
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Kooresh Shoghi
Professor
Washington University in St. Louis
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Meenhard Herlyn
Professor, Director
The Wistar Institute
Jason M. Held
Washington University School of Medicine
Xuelin Huang
Professor
The University of Texas MD Anderson Cancer Center
John F. DiPersio
Director, Center for Gene and Cellular Immunotherapy
Washington University in St. Louis
Shunqiang Li
Associate Professor
Washington University in St. Louis
Ying Zhu
Genentech Inc
Scott Goldsmith
Assistant Professor
City Of Hope National Medical Center
Kian-Huat Lim
Associate Professor
Washington University
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Luis G Carvajal‐Carmona
Professor
University of California, Davis
Michael Province
Professor, Head Division of Statistical Genomics
Washington University in St. Louis
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Robert Mashl
Washington University in St. Louis
Chong-xian Pan
Professor
university of california davis medical center
Tao Liu
Sr. Staff Scientist
Pacific Northwest National Laboratory
Carol Bult
Professor and Knowlton Family Chair
Jackson Laboratory
Ravi Vij
Washington University School of Medicine
Chia-Feng Tsai
Scorpion Therapeutics (United States)
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Leah Gehrs
The University of Alabama
Carlos Cruchaga
Professor
Washington University in St. Louis
J. Chuck Harrell
Virginia Commonwealth University
Michael Lewis
Baylor College of Medicine
jingqin luo
Associate Professor
Washington University in Saint Louis School of Medicine
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Soner Koc
GlaxoSmithKline Research and Development
Michael Rettig
Washington University in St. Louis
Guanghua Xiao
-
Yang Xie
Professor
University of Texas Southwestern Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.